QIAGEN Posts 2014 Annual Report on Its Website
Venlo, The Netherlands (ots/PRNewswire) -
QIAGEN N.V. has posted its 2014 Annual Report on its website at h
ttp://www.qiagen.com/About-Us/Investors/Financial-Information/Financi
al-Reports QIAGEN's Annual Report on Form 20-F for the year ended
December 31, 2014 has been filed with the U.S. Securities and
Exchange Commission (SEC) on February 27, 2015, a copy of which can
be found on the website of the SEC at http://www.sec.gov or in the
'Financial Information' section of the 'Investors' section of our
website at http://www.qiagen.com/About-Us/Investors . QIAGEN will
provide printed copies of the 2014 Annual Report to shareholders free
of charge upon request. To obtain a printed copy of the 2014 Annual
Report please contact: IR@qiagen.com.
About QIAGEN
QIAGEN N.V. has posted its 2014 Annual Report on its website at h
ttp://www.qiagen.com/About-Us/Investors/Financial-Information/Financi
al-Reports QIAGEN's Annual Report on Form 20-F for the year ended
December 31, 2014 has been filed with the U.S. Securities and
Exchange Commission (SEC) on February 27, 2015, a copy of which can
be found on the website of the SEC at http://www.sec.gov or in the
'Financial Information' section of the 'Investors' section of our
website at http://www.qiagen.com/About-Us/Investors . QIAGEN will
provide printed copies of the 2014 Annual Report to shareholders free
of charge upon request. To obtain a printed copy of the 2014 Annual
Report please contact: IR@qiagen.com.
About QIAGEN
Anzeige
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions to transform
biological materials into valuable molecular insights. QIAGEN sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics software
and knowledge bases interpret data to report relevant, actionable
insights. Automation solutions tie these together in seamless and
cost-effective molecular testing workflows. QIAGEN provides these
workflows to more than 500,000 customers around the world in
Molecular Diagnostics (human healthcare), Applied Testing (forensics,
veterinary testing and food safety), Pharma (pharmaceutical and
biotechnology companies) and Academia (life sciences research). As of
December 31, 2014, QIAGEN employed approximately 4,300 people in over
35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Investor Relations:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
+1-240-686-2222
Email: ir@qiagen.com
ots Originaltext: Qiagen N.V.
Im Internet recherchierbar: http://www.presseportal.de
global provider of Sample to Insight solutions to transform
biological materials into valuable molecular insights. QIAGEN sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics software
and knowledge bases interpret data to report relevant, actionable
insights. Automation solutions tie these together in seamless and
cost-effective molecular testing workflows. QIAGEN provides these
workflows to more than 500,000 customers around the world in
Molecular Diagnostics (human healthcare), Applied Testing (forensics,
veterinary testing and food safety), Pharma (pharmaceutical and
biotechnology companies) and Academia (life sciences research). As of
December 31, 2014, QIAGEN employed approximately 4,300 people in over
35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Investor Relations:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
+1-240-686-2222
Email: ir@qiagen.com
ots Originaltext: Qiagen N.V.
Im Internet recherchierbar: http://www.presseportal.de
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte